{
    "clinical_study": {
        "@rank": "45188", 
        "arm_group": [
            {
                "arm_group_label": "sequence 1 : Test drug - Reference", 
                "arm_group_type": "Other"
            }, 
            {
                "arm_group_label": "Sequence 2 : Reference - Test drug", 
                "arm_group_type": "Other"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the bioequivalence (comparison of the rate and\n      extent of the active substance into the body following single administration of the drugs)\n      between the test product V0057  and a reference product after two single oral administration\n      separate by 7 days."
        }, 
        "brief_title": "Bioequivalence Study of V0057 Versus a Reference Formulation After Single Administration in Healthy Male Subjects", 
        "completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy Volunteers", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy male subject aged 18 to 50 years (inclusive)\n\n        Exclusion Criteria:\n\n          -  Presence of any significant medical finding or significant history that may impact\n             the safety, the interpretation of the results and/or the participation of the subject\n             in the study according to the opinion of the investigator\n\n          -  Presence of any clinically significant abnormal finding at examination in the\n             Investigator's opinion"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "45", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01861626", 
            "org_study_id": "V00057 CA 1 01", 
            "secondary_id": "2013-000988-80"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "sequence 1 : Test drug - Reference", 
                    "Sequence 2 : Reference - Test drug"
                ], 
                "description": "Single oral administration", 
                "intervention_name": "V0057 - A mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "sequence 1 : Test drug - Reference", 
                    "Sequence 2 : Reference - Test drug"
                ], 
                "description": "Single oral administration", 
                "intervention_name": "Isotretinoin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Isotretinoin"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "June 18, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Erfurt", 
                    "country": "Germany", 
                    "zip": "D-99084"
                }
            }
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "Germany: Ethics Commission"
            ]
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Maximum Plasma Concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "18 time points up to 72h after administration"
            }, 
            {
                "measure": "Time of Maximum Concentration (Tmax)", 
                "safety_issue": "No", 
                "time_frame": "18 time points up to 72h after administration"
            }, 
            {
                "measure": "Area under curve (AUC0-72)", 
                "safety_issue": "No", 
                "time_frame": "18 time points up to 72h after administration"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01861626"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Pierre Fabre Dermatology", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pierre Fabre Dermatology", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}